Represents net earnings attributable to AbbVie Inc. Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset acquired as ...

Perhaps shortly after this came the sales forecasts, which at the time were in the region of $5 billion per year at peak. It wasn’t a Humira, but AbbVie was realistic enough to accept that it ...

Other recent partnerships in the molecular glue degrader category include Takeda's recent $1 billion-plus link-up with Degron Therapeutics, a $1.46 billion deal between Novo Nordisk and Neomorph ...